#4-09E. The Ultimate Immune Reset: Dual-Targeting CAR-T Therapy in SLE (Arthritis Rheumatol, 2026)

What is the next frontier in treating refractory systemic lupus erythematosus (SLE) when conventional therapies fail? This study evaluates peripheral blood mononuclear cells from SLE patients treated with dual-targeting BCMA-CD19 CAR-T cell therapy utilizing single-cell RNA sequencing and immune repertoire profiling. The results demonstrate a profound depletion of plasma-lineage clusters that typically persist after CD19 single-targeting therapy, alongside a reconstruction of the B cell receptor repertoire toward a healthy, naïve-biased state. The most critical clinical finding is that this dual-targeting approach achieves a significantly deeper depletion of pathogenic plasma cell lineages, facilitating a powerful humoral immune reset. However, when critically appraising this study, clinicians must note that the cohort size is extremely small, with only five patients, and the comparison to CD19-only therapy relies on indirect, cross-cohort analysis. Despite these limitations, this paper is highly relevant for rheumatologists and physicians, as it highlights a potential paradigm shift toward curative cellular therapies for treatment-resistant SLE, paving the way for achieving comprehensive and durable immune remission in future clinical practice.

Citation: He, Zhenghao, et al. Dual-Targeting BCMA–CD19 CAR-T Cell Therapy in Systemic Lupus Erythematosus: Single-Cell and Immune Repertoire Analysis Reveals Mechanisms of Immune Reconstitution. Arthritis & Rheumatology. 2026. DOI: 10.1002/art.70117

Disclaimer: This audio summary is based on personal interpretation and does not guarantee the exact content of the original paper. Please refer to the original article for details.